

December 20, 2016

Novartis Pharma AG

CH-4002, Basel, Switzerland

Reference: EudraCT 2013-005014-34/ Novartis Protocol ID CLGX818A2202

*A phase II, single arm, open-label, multicenter, study of oral LGX818 in patients with BRAF V600 mutant advanced non-small cell lung cancer that have progressed during or after at least one prior chemotherapy*

Trial CLGX818A2202 was cancelled with no patient enrollment and as such, no results will be reported.